| PFG |
Report |
Core EPS |
BEAT |
pred ~$2.39 vs. cons $2.35 |
MEDIUM |
| PFG |
Report |
Specialty Benefits loss ratio |
BEAT |
pred ~59.5% vs. cons 60.45% |
MEDIUM |
| PFG |
Report |
Investment Management net cash flow |
BEAT |
pred ~-$4.8B vs. cons -$5.49B |
LOW |
| PFG |
Guide |
FY26 Core EPS growth (FY26) |
UNCHANGED |
guide ~9%-12% vs. consensus growth ~11.9% |
MEDIUM |
| PFG |
Guide |
Specialty Benefits loss-ratio outlook (FY26) |
UNCHANGED |
guide ~low end/slightly below low end vs. FY consensus 59.28% |
MEDIUM |
| PFG |
Guide |
Investment Management flow outlook (FY26) |
UNCHANGED |
guide ~improving profile vs. FY consensus -$10.87B |
LOW |
| PFG |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
LOW |
| PFG |
Return |
5-day cumulative residual |
-2.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — implicit out-period-estimate risk |
LOW |